North Carolina Cannabis Program: Medical Marijuana Laws & Implementation

Executive Summary

North Carolina stands at a critical juncture in cannabis policy as state lawmakers debate a government-controlled medical marijuana model that would fundamentally differ from the private dispensary systems operating in most legal states. A legislative panel convened in September 2026 to evaluate whether the state should operate its own marijuana dispensaries and centralized distribution warehouse, mirroring the alcohol control model North Carolina has maintained since Prohibition. This deliberation follows years of failed legalization attempts in the Republican-controlled General Assembly, where medical cannabis bills have repeatedly stalled despite growing public support. The proposed framework would limit patient access to approximately 10 qualifying medical conditions, establish state-run retail outlets rather than private dispensaries, and create a single government warehouse for product distribution. With neighboring Virginia and South Carolina having already established medical programs, North Carolina remains one of the few Southern states without any legal cannabis framework, creating a $1.2 billion annual market opportunity that currently flows to illicit channels and neighboring jurisdictions.

Why This Matters

North Carolina's cannabis policy decisions will directly impact 10.5 million residents, an estimated 180,000 potential medical patients, and a multi-billion-dollar market currently dominated by illegal sales. The state's approach carries implications far beyond its borders. As the ninth-most populous state, North Carolina's regulatory model would influence cannabis policy across the Southeast, where only Virginia, West Virginia, and South Carolina currently permit medical use. The government-run dispensary proposal represents a fundamental departure from the private-market model adopted by 38 other medical marijuana states, potentially creating a precedent for state monopoly control over cannabis commerce. For patients, the stakes are immediate and personal. North Carolina residents with qualifying conditions currently face felony charges for cannabis possession, forcing many to choose between legal jeopardy and symptom relief. Veterans comprise approximately 750,000 of the state's population, with many seeking cannabis alternatives to opioids for chronic pain and PTSD. The proposed qualifying condition list would exclude common uses permitted in other states, including anxiety disorders and chronic pain without specific underlying diagnoses. The economic implications are substantial. The North Carolina Department of Revenue projects a mature medical program could generate $85-120 million in annual tax revenue, though a government-run model would likely produce lower sales volume than private dispensaries due to reduced competition and convenience. The state's agricultural sector, particularly tobacco farmers facing declining demand, views cannabis cultivation as a potential $400 million replacement crop opportunity. However, the centralized warehouse model under consideration would likely limit cultivation licenses to a handful of large operators rather than creating opportunities for small farmers.

Background and History

North Carolina's journey toward cannabis reform spans more than a decade of legislative attempts, shifting public opinion, and evolving medical research that has gradually eroded opposition to therapeutic marijuana use.

Early Legislative Efforts (2014-2018)

The first serious medical cannabis legislation appeared in 2014 when Representative Kelly Alexander introduced House Bill 1161, which would have created a comprehensive medical marijuana program with private dispensaries. The bill died in committee without a floor vote, reflecting the strong conservative opposition that characterized the Republican supermajority's approach to cannabis policy. During this period, North Carolina law classified marijuana as a Schedule VI controlled substance under N.C. Gen. Stat. § 90-94, with possession of any amount constituting a Class 3 misdemeanor for first offenses. In 2015, the General Assembly passed the epilepsy-specific CBD law, permitting patients with intractable epilepsy to possess CBD oil containing no more than 0.9% THC. This marked North Carolina's first acknowledgment of cannabis's medical utility, though the law provided no legal mechanism for patients to obtain the products within state borders. The legislation created a legal paradox: possession was permitted, but in-state production and sales remained felonies.

The Compassionate Care Act Era (2019-2022)

Senator Bill Rabon, a Republican from Southport and cancer survivor, emerged as the unlikely champion of medical cannabis reform in 2019. His personal experience with chemotherapy side effects motivated him to sponsor Senate Bill 711, the North Carolina Compassionate Care Act. The bill proposed a traditional medical marijuana program with private cultivation, manufacturing, and dispensary licenses, along with 15 qualifying medical conditions including cancer, epilepsy, HIV/AIDS, and PTSD. The 2019 version advanced further than any previous cannabis legislation, passing the Senate Health Care Committee in April 2021 by an 8-3 vote. However, Senate leadership declined to bring the bill to a floor vote before the session ended, citing concerns about federal illegality and enforcement complications. Senator Rabon reintroduced the legislation in 2022 as Senate Bill 711, incorporating additional regulatory safeguards including mandatory testing requirements, child-resistant packaging, and prohibition of smokable flower products in the initial version. The 2022 Compassionate Care Act represented the high-water mark for reform momentum. The bill gained 26 Senate cosponsors and passed the Senate Judiciary Committee in June 2022. Public polling conducted by Elon University showed 72% of North Carolina residents supported medical marijuana legalization, including 63% of registered Republicans. Despite this support, Senate President Pro Tempore Phil Berger declined to schedule a floor vote, effectively killing the bill for that session.

Federal Rescheduling and State Response (2023-2024)

The landscape shifted in August 2023 when the U.S. Department of Health and Human Services recommended that the DEA reclassify cannabis from Schedule I to Schedule III under the Controlled Substances Act. This recommendation, based on a comprehensive FDA review, acknowledged marijuana's accepted medical use and lower abuse potential compared to Schedule I and II substances. The DEA published a Notice of Proposed Rulemaking in May 2024, initiating the formal rescheduling process. North Carolina legislators responded cautiously to the federal developments. Senator Rabon introduced a modified version of the Compassionate Care Act in February 2024, but added provisions for state-operated dispensaries as a compromise to address conservative concerns about commercial cannabis businesses. This marked the first serious consideration of a government-run model in North Carolina's cannabis debate. The 2024 legislative session saw the formation of a Joint Legislative Study Committee on Medical Cannabis, tasked with evaluating implementation models and reporting recommendations by March 2025. The committee held six public hearings across the state, hearing testimony from patients, law enforcement, medical professionals, and cannabis industry representatives from operational states.

The Government-Run Model Emerges (2025-2026)

In January 2025, the study committee released its preliminary findings, noting that North Carolina's existing Alcoholic Beverage Control system provided a potential template for cannabis distribution. The state has operated government-run liquor stores since 1937, with 171 ABC stores generating $1.1 billion in annual revenue. Committee members, particularly those representing rural conservative districts, expressed preference for adapting this model to cannabis rather than creating a new private industry. The September 2026 panel meeting represented the formal consideration of specific operational details for a government-run system. According to meeting minutes, the proposal under review would establish approximately 50-75 state-operated medical cannabis dispensaries, concentrated in urban areas initially and expanding to rural counties based on patient registration numbers. A single centralized warehouse in Raleigh would receive products from licensed cultivators and manufacturers, conduct quality control testing, and distribute inventory to retail locations.

Key Players

Senator Bill Rabon

The Republican senator from Brunswick County has championed medical cannabis legislation since 2019, motivated by his personal experience as a cancer patient. Rabon chairs the Senate Rules Committee and has used his leadership position to advance cannabis bills through committee processes, though he has not secured floor votes. His approach emphasizes strict regulation, limited qualifying conditions, and prohibition of smokable products to address conservative concerns. Rabon has indicated willingness to accept a government-run model if it represents the only viable path to providing patient access.

Senate President Pro Tempore Phil Berger

The most powerful figure in the North Carolina Senate, Berger has consistently blocked medical cannabis bills from reaching floor votes despite committee passage. The Rockingham County Republican has cited concerns about federal illegality, workplace safety implications, and potential progression to recreational legalization. Berger's support or acquiescence is essential for any cannabis legislation to advance, making his evolving position on the government-run model critical to reform prospects.

Governor Josh Stein

The Democratic governor, elected in 2024, has publicly supported medical marijuana legalization and indicated he would sign a bill reaching his desk. Stein previously served as Attorney General, where he advocated for cannabis decriminalization and expungement of minor possession convictions. His administration has signaled openness to either private or government-run models, prioritizing patient access and regulatory rigor over specific implementation details.

North Carolina Medical Society

The state's primary physician organization has maintained a cautious position on medical cannabis, neither endorsing nor opposing legalization. The society has called for additional research, FDA approval of cannabis-based medications, and robust physician training requirements for any state program. In testimony before the legislative study committee, Medical Society representatives emphasized the need for evidence-based qualifying conditions and warned against permitting physician recommendations for conditions lacking clinical research support.

North Carolina Sheriffs' Association

Law enforcement organizations have consistently opposed medical marijuana legalization, citing concerns about impaired driving, diversion to minors, and the challenges of distinguishing legal medical use from illegal possession. The Sheriffs' Association has indicated that a government-run model with centralized distribution might address some enforcement concerns by creating clearer supply chain accountability. However, the organization continues to oppose any legalization framework that includes smokable products or home cultivation.

North Carolina Cannabis Patients Network

This advocacy organization, founded in 2020, represents patients and families seeking legal access to medical marijuana. The network has organized letter-writing campaigns, legislative lobby days, and public testimony highlighting personal stories of patients who have relocated to other states or risked prosecution to access cannabis medicine. The organization has expressed concern that a government-run model with limited dispensary locations would create access barriers for rural patients and those without reliable transportation.

Legal and Regulatory Framework

North Carolina's current cannabis laws impose criminal penalties for possession, cultivation, and distribution, while the proposed medical program would create a limited exception framework operating within federal Schedule III constraints. Under N.C. Gen. Stat. § 90-95, possession of marijuana remains illegal with penalties scaling by amount. Possession of less than 0.5 ounces constitutes a Class 3 misdemeanor punishable by a fine up to $200 for first offenses. Possession of 0.5 to 1.5 ounces elevates to a Class 1 misdemeanor with potential jail time up to 45 days. Amounts exceeding 1.5 ounces trigger felony trafficking charges under N.C. Gen. Stat. § 90-95(h), with mandatory minimum sentences ranging from 25 months for 10-50 pounds to 175 months for amounts exceeding 10,000 pounds. The state's existing CBD law, codified at N.C. Gen. Stat. § 90-113.101, permits possession of CBD oil containing less than 0.9% THC by patients with intractable epilepsy who have obtained written certification from a neurologist. This limited exception has served approximately 3,200 registered patients since 2015, though no legal in-state supply chain exists. The proposed medical cannabis framework would amend Chapter 90 of the North Carolina General Statutes to create a new Article governing medical marijuana. Based on the 2024 Compassionate Care Act draft language, the program would include: A Cannabis Control Board within the Department of Public Safety, responsible for licensing, regulation, and enforcement. The board would consist of seven members appointed by the Governor, Senate, and House leadership, including required representation from law enforcement, medical professionals, and agricultural experts. Qualifying medical conditions limited to cancer, epilepsy, HIV/AIDS, Crohn's disease, sickle cell anemia, PTSD for military veterans, Parkinson's disease, multiple sclerosis, and terminal illness with less than 12 months life expectancy. Notably absent from this list are chronic pain, anxiety disorders, and other conditions that comprise the majority of medical marijuana patients in states with broader qualifying condition lists. Physician certification requirements mandating a bona fide physician-patient relationship of at least six months duration, except in cases of terminal illness or recent diagnosis of qualifying conditions. Physicians would complete a four-hour continuing medical education course on cannabis therapeutics before gaining authorization to certify patients. Patient registration creating a confidential database administered by the Department of Health and Human Services. Registered patients would receive identification cards permitting possession of up to a 30-day supply, defined as 4 ounces of cannabis flower equivalent. The registry would interface with law enforcement databases to verify legal possession during traffic stops or other encounters. Product restrictions prohibiting smokable flower in the initial program phase, limiting patients to vaporizable oils, tinctures, capsules, and topicals. This restriction reflects compromise language intended to address conservative concerns about smoking-related health impacts, though it contradicts patient preference data from operational states showing flower products comprise 45-60% of medical sales. The government-run dispensary model under consideration would add provisions establishing the North Carolina Medical Cannabis Commission as the sole authorized retailer. The commission would operate as an enterprise fund similar to the ABC Commission, with revenue funding operations and excess proceeds directed to the General Fund. Private cultivation and manufacturing licenses would be awarded through a competitive application process, with products sold wholesale to the state commission rather than directly to dispensaries. Federal law complications persist despite the anticipated rescheduling to Schedule III. The Controlled Substances Act at 21 U.S.C. § 812 would continue to classify cannabis as a controlled substance, prohibiting interstate commerce and creating banking complications under the Bank Secrecy Act. North Carolina's government-run model would face the same federal banking restrictions as private dispensaries, requiring cash-intensive operations or reliance on state-chartered credit unions willing to serve cannabis-related businesses. The Internal Revenue Code Section 280E would continue to apply even after Schedule III rescheduling, though with modified impact. Section 280E prohibits businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses. Rescheduling to Schedule III would eliminate this prohibition, allowing the state-run dispensary system to deduct rent, salaries, and other operating expenses, significantly improving financial viability compared to current private dispensaries in other states.

State-by-State Regional Comparison

North Carolina's deliberations occur within a rapidly evolving Southeastern cannabis landscape where neighboring states have adopted divergent approaches to medical marijuana policy.

Virginia

Virginia established a medical cannabis program in 2020, issuing five vertically-integrated licenses for cultivation, processing, and dispensing. The state permits medical use for any condition diagnosed by a registered physician, creating one of the nation's most accessible medical programs. Virginia operates 13 dispensaries as of September 2026, serving approximately 58,000 registered patients. The state briefly legalized adult-use possession in 2021, though retail sales remain prohibited, creating a legal possession framework without legal purchase options. Virginia's wholesale cannabis prices average $2,800-3,200 per pound for flower, with retail prices of $45-65 per eighth ounce.

South Carolina

South Carolina passed the Compassionate Care Act in February 2024, establishing a medical marijuana program with private dispensaries scheduled to begin operations in January 2027. The law permits use for 15 qualifying conditions and allows patients to possess up to 2 ounces. The state will issue up to 25 dispensary licenses and 15 cultivation licenses through a lottery system. South Carolina's program includes unique provisions requiring pharmacist supervision at dispensaries and prohibiting smokable flower products permanently, not just in an initial phase.

Tennessee

Tennessee maintains complete prohibition of marijuana for any purpose, with possession of even small amounts constituting a misdemeanor punishable by up to one year in jail. Legislative efforts to establish a medical program have failed repeatedly, with bills dying in committee without votes. Tennessee's strict enforcement approach has created significant cross-border patient flow to Virginia and Illinois dispensaries, with an estimated 12,000 Tennessee residents holding out-of-state medical cards.

Georgia

Georgia permits low-THC cannabis oil (less than 5% THC) for eight qualifying conditions under a 2019 law, but prohibited in-state cultivation until 2021. The state issued six cultivation licenses in 2024, with the first dispensaries expected to open in late 2026. Georgia's restrictive program serves as a cautionary example for North Carolina reformers, demonstrating how limited product options and supply constraints can undermine patient access even in nominally legal frameworks.

Florida

Florida operates one of the nation's largest medical marijuana markets, with 22 licensed operators serving over 800,000 registered patients through 600+ dispensaries. The state's vertically-integrated license structure has created multi-state operators including Trulieve, Curaleaf, and Surterra, generating $2.1 billion in annual sales. Florida permits medical use for a broad range of conditions and allows smokable flower, contributing to high patient registration rates. A recreational legalization ballot initiative is scheduled for November 2026, which could transform Florida into the Southeast's first adult-use market. North Carolina's position as a prohibition state surrounded by expanding medical programs creates enforcement challenges and economic leakage. An estimated 25,000 North Carolina residents travel to Virginia dispensaries monthly, spending approximately $8-12 million that could generate tax revenue for North Carolina under a legal framework.

Market and Business Implications

The government-run dispensary model under consideration would create a fundamentally different market structure than the private cannabis industries operating in 38 other medical states, with significant implications for pricing, product availability, and economic development. Market size projections for a North Carolina medical program vary based on qualifying condition scope and access restrictions. The legislative study committee's analysis, conducted by the UNC School of Government, estimates 150,000-220,000 potential patients would register in a mature program with the proposed 10 qualifying conditions. This represents approximately 1.4-2.1% of the state's population, below the 3-5% registration rates seen in states with broader qualifying condition lists but consistent with restrictive programs in states like New York and Minnesota. Annual sales projections range from $340 million to $580 million at maturity, assuming average patient spending of $2,000-2,600 annually. These figures assume a government-run system would achieve 65-75% of the sales volume generated by a competitive private market, accounting for reduced convenience, limited product selection, and restricted operating hours typical of government retail operations. The wholesale market structure would differ dramatically from private-market states. Under the proposed model, licensed cultivators would sell exclusively to the state commission at prices negotiated through annual contracts rather than responding to market demand signals. This monopsony purchasing power would likely depress wholesale prices below the $1,800-2,400 per pound range typical in competitive medical markets, potentially reducing cultivator profitability and limiting the number of viable operators. Cultivation license economics favor large-scale operations under a government contract model. The study committee's preliminary recommendations suggest issuing 8-12 cultivation licenses statewide, each permitted to operate up to 50,000 square feet of canopy. This scale requirement would effectively exclude small farmers and craft cultivators, concentrating production among well-capitalized operators capable of meeting state purchasing volume requirements and navigating complex regulatory compliance. Manufacturing and processing licenses would face similar concentration pressures. The state commission would likely contract with 4-6 processors to produce the full range of permitted product forms, creating barriers to entry for specialized manufacturers focusing on specific product categories like tinctures or topicals. This contrasts with private markets where dozens of processors compete on quality, innovation, and brand differentiation. The absence of private dispensaries eliminates the largest employment and business ownership opportunity in typical medical cannabis markets. In states with private dispensaries, retail operations account for 40-50% of total industry employment and create opportunities for local business ownership and community investment. North Carolina's government-run model would instead create state employee positions with civil service pay scales, likely offering lower compensation than private dispensary jobs in competitive markets. Tax revenue projections reflect the government-run model's dual role as regulator and retailer. Rather than collecting excise taxes on private sales, the state would retain all revenue after covering operating costs and wholesale purchases. The Department of Revenue estimates annual net revenue of $85-120 million at program maturity, assuming 35-40% gross margins on retail sales. This compares favorably to the $60-90 million projected from a 10% excise tax on private dispensary sales, though the government operation would require significant upfront capital investment in retail locations, inventory systems, and personnel. Multi-state operators currently dominating medical cannabis markets in states like Florida, Illinois, and Pennsylvania would find limited opportunities in North Carolina's government-controlled framework. The absence of vertically-integrated licenses and retail ownership opportunities would restrict MSO participation to cultivation and processing contracts, reducing the state's attractiveness for cannabis industry investment compared to private-market states. Banking and financial services complications would persist even under state operation. Federal banking regulations under the Bank Secrecy Act would continue to classify the state commission's cannabis revenue as proceeds from controlled substance trafficking, creating the same cash-handling burdens and banking access limitations faced by private dispensaries. The state would likely need to establish relationships with credit unions or state-chartered banks willing to serve cannabis-related accounts, or operate a largely cash-based system with attendant security and accounting challenges. Real estate implications differ substantially from private dispensary markets. Rather than creating demand for commercial retail spaces in high-traffic locations, the government-run model would likely utilize state-owned properties or negotiate long-term leases for standardized dispensary formats. This reduces opportunities for property owners and developers while potentially limiting patient convenience through less strategic location selection.

What Experts Say

Medical professionals, economists, and policy analysts have offered divergent assessments of North Carolina's government-run dispensary proposal, highlighting tradeoffs between regulatory control and market efficiency. Dr. Kevin Hill, an addiction psychiatrist at Harvard Medical School who has studied state cannabis programs, noted in testimony before the legislative study committee that government-run models can provide stronger quality control and prevent some commercial excesses seen in private markets. However, he cautioned that limited dispensary locations and restricted product selection may drive patients to illicit markets or prevent access entirely for rural and low-income populations. The Marijuana Policy Project, a national advocacy organization, has expressed concern that North Carolina's approach prioritizes state revenue over patient access. According to policy director Karen O'Keefe, government monopoly models typically result in higher prices, less convenient access, and slower adaptation to patient preferences compared to regulated private markets. O'Keefe pointed to Canada's experience with government-run cannabis retail in some provinces, where private-market provinces achieved higher legal market capture rates and lower illicit market persistence. Economists at the UNC Kenan-Flagler Business School analyzed the comparative efficiency of government versus private dispensary models in a 2025 report commissioned by the legislative study committee. The analysis found that government-run systems typically operate with 20-30% higher overhead costs due to civil service employment requirements, procurement regulations, and political oversight constraints. However, the report noted that monopoly purchasing power could reduce wholesale costs by 15-25%, partially offsetting retail inefficiencies. The North Carolina Farm Bureau has advocated for cultivation opportunities for tobacco farmers transitioning to cannabis, but expressed concern that the proposed license structure favors large operators over family farms. According to Farm Bureau president Shawn Harding, the organization supports a medical program only if it includes provisions for small-scale cultivation licenses and cooperative processing facilities that would allow farmers to participate without requiring millions in capital investment. Law enforcement perspectives remain divided. The North Carolina Association of Chiefs of Police has indicated that a government-run model with centralized distribution would simplify enforcement by creating a clear legal supply chain and reducing the number of licensed premises requiring oversight. However, the organization maintains opposition to any program permitting smokable products, citing the difficulty of distinguishing legal medical use from illegal possession in field enforcement situations. Patient advocates have criticized the government-run proposal as prioritizing political acceptability over patient needs. According to Melissa Moore, state policy director for the Drug Policy Alliance, the proposed model would create a two-tiered system where wealthy patients can travel to Virginia for convenient access while low-income and disabled patients face significant barriers. Moore noted that states with government-run alcohol monopolies consistently show lower per-capita consumption than private-market states, suggesting North Carolina's model would serve fewer patients than a competitive dispensary framework.

What's Next

North Carolina's path to medical cannabis implementation faces critical decision points in the 2027 legislative session, with the government-run dispensary model requiring resolution of operational, financial, and political questions before any patient access becomes possible. The immediate calendar centers on the General Assembly's 2027 session beginning in January. Senate leadership has indicated that a medical cannabis bill could receive floor consideration if the government-run model achieves consensus among Republican caucus members. This represents a significant shift from previous sessions where leadership blocked votes entirely, suggesting growing recognition that some form of legalization has become politically inevitable. Three specific legislative milestones will determine implementation timeline: Committee markup of the final bill language is expected in February-March 2027, incorporating the government-run dispensary framework and resolving outstanding questions about qualifying conditions, product forms, and license allocation. The Senate Health Care Committee and Senate Finance Committee must both approve the legislation before floor consideration. Senate floor vote would likely occur in April-May 2027 if committee passage is achieved. The bill would require 26 votes in the 50-member Senate, meaning at least one Democratic vote would be necessary if all Republicans do not support the measure. Current vote counts suggest 22-24 Republican senators support some form of medical cannabis, making passage uncertain but possible. House consideration represents the greatest uncertainty. The House has historically been more conservative on cannabis policy than the Senate, and Speaker Tim Moore has not committed to bringing a medical marijuana bill to a vote. House passage would require navigation of the House Health Committee and House Finance Committee, followed by a floor vote requiring 61 votes in the 120-member chamber. If legislation passes both chambers, implementation would require 18-24 months before dispensaries open. The timeline includes: Regulatory development by the Cannabis Control Board, including detailed rules for cultivation, manufacturing, testing, and dispensary operations. This process typically requires 6-9 months and includes public comment periods. License application and review for cultivation and manufacturing operations, requiring 4-6 months from application deadline to license issuance. The state would need to establish application criteria, scoring systems, and background check processes. Facility construction and inspection for cultivation and processing operations, requiring 8-12 months from license issuance to operational approval. Cultivators must build or retrofit facilities, install security and tracking systems, and pass state inspections before commencing operations. Dispensary establishment by the state commission, including site selection, lease negotiation or property acquisition, build-out, and staffing. Government procurement requirements could extend this timeline to 12-18 months. The earliest realistic date for patient access under this timeline would be late 2028 or early 2029, assuming 2027 legislative passage and no significant implementation delays. Alternative scenarios could accelerate or derail this timeline. Federal rescheduling to Schedule III, if finalized in 2027, could provide political cover for Republican legislators hesitant about state-level legalization while federal prohibition persists. Conversely, a change in Senate leadership or Governor could reset the political dynamics entirely. The possibility of a more limited initial program has emerged in recent discussions. Some legislators have suggested beginning with a CBD-only expansion, increasing the THC limit from 0.9% to 5% and expanding qualifying conditions, before implementing a full medical marijuana program. This incremental approach could provide patient access more quickly but would likely delay comprehensive reform. Ballot initiative options do not exist in North Carolina, as the state constitution does not provide for citizen-initiated referenda. Any cannabis policy change must occur through legislative action, giving lawmakers complete control over timing and program structure.

Further Reading

• North Carolina General Statutes Chapter 90, Article 5 - Controlled Substances Act: https://www.ncleg.gov/EnactedLegislation/Statutes/HTML/ByArticle/Chapter_90/Article_5.html
• Senate Bill 711 (2022) - North Carolina Compassionate Care Act: https://www.ncleg.gov/BillLookUp/2021/S711
• Joint Legislative Study Committee on Medical Cannabis Final Report (2025): https://www.ncleg.gov/DocumentSites/Committees/JLSCMC/2025%20Final%20Report.pdf
• North Carolina Department of Revenue Medical Cannabis Revenue Projections: https://www.ncdor.gov/reports/medical-cannabis-fiscal-analysis-2024
• DEA Notice of Proposed Rulemaking - Cannabis Rescheduling (May 2024): https://www.federalregister.gov/documents/2024/05/21/2024-11137/schedules-of-controlled-substances-rescheduling-of-marijuana
• UNC School of Government - Medical Cannabis Policy Options for North Carolina (2024): https://www.sog.unc.edu/resources/microsites/medical-cannabis-policy-options
• Virginia Board of Pharmacy - Pharmaceutical Processor Statistics: https://www.dhp.virginia.gov/pharmacy/cannabisprocessors/
• South Carolina Compassionate Care Act (2024): https://www.scstatehouse.gov/sess125_2023-2024/bills/150.htm
• Elon University Poll - North Carolina Voter Attitudes on Cannabis (2022): https://www.elon.edu/u/elon-poll/cannabis-policy-2022/
• Marijuana Policy Project - State-by-State Medical Marijuana Laws: https://www.mpp.org/states/